Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
05:42 | BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium | ||
05:42 | BRIEF: SF Intra-city's profit doubles in 2024 | ||
04:42 | What's Ahead for China Inc. Under Trump 2.0? | ||
04:42 | ACM Research straddles growing U.S.-China microchip divide | ||
Mo | BRIEF: Abbisko moves into the black in 2024 | ||
Mo | BRIEF: 'Sauerkraut Fish' parent Jiumaojiu reports sharp same-store sales declines | ||
Mo | NEWS WRAP: Profit plunges at JinkoSolar's main China-listed unit | ||
Mo | Zhengye Biotech's 'pet-sized' IPO leaves plenty of room for more fundraising | ||
Fr | DouYu names new CEO, declares massive dividend to entice investors | ||
Fr | SPONSORED: ARK Wealth outlines global asset allocation strategies at inaugural flagship summit | ||
Fr | BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales | ||
Fr | BRIEF: Coland Ocean secures CSRC approval for Hong Kong IPO | ||
Fr | Miniso looks to spread the love for cute and collectible trinkets | ||
Fr | BRIEF: Lifestyle China raises privatization offer price | ||
Fr | Shanghai family feud ties up $1 billion in property, offers lesson for investors | ||
Do | BRIEF: China Tourism Group Duty Free's revenue, profit decline in 2024 | ||
Do | BRIEF: China Traditional Chinese Medicine's profit tumbles in 2024 | ||
Do | BRIEF: Li Ning returns as sponsor of China's Olympic delegation | ||
Do | WuXi Biologics sells vaccine plant as new U.S. law looms | ||
Mi | BRIEF: WuXi XDC's revenue, profit jump in 2024 | ||
Mi | BRIEF: Leapmotor becomes profitable a year ahead of schedule | ||
Mi | Yibin Bank's IPO spotlights challenges facing regional lenders | ||
Mi | Alibaba's Sun Art Sale, and a China-Kazakhstan Dual Listing | ||
Mi | Let's 'Eat Goods!" China's $23 billion animation derivatives market is no game | ||
Mi | BRIEF: Saimo Technology ticks up in Hong Kong trading debut |